
A team at the National Institute of Oncology in Warsaw has received a grant to develop TIL therapy for ovarian cancer, Prof. Piotr Rutkowski of the institute told the Polish Press Agency (PAP). The therapy uses T cells from the patient’s own tumor. Rutkowski said the team also plans to study the approach in skin carcinomas and melanoma.
In the interview, published on November 19, Rutkowski explained why researchers start with a tumor sample. Some of the T cells that have entered the tumor already recognize the cancer cells. TIL stands for tumor-infiltrating lymphocytes. Researchers isolate these immune cells from a sample of tumor tissue and grow them in the laboratory so they can give the patient back a larger number of their own cells.
Rutkowski said the institute already has a laboratory that develops cell therapies under Good Manufacturing Practice (GMP) standards. The institute is also preparing space for patients to receive cell therapies. He compared the conditions those patients will need to those required for people undergoing bone marrow transplants.
Sources
- Nauka w Polsce · Fundacja PAP — Źródło: Nauka w Polsce (Fundacja PAP) (https://naukawpolsce.pl/) · Source date: 2026-11-19
Independent editorial content. WUA is not affiliated with any political party. 2026-11-19